trending Market Intelligence /marketintelligence/en/news-insights/trending/XZ9qFw_M54JpFxAtrEo1xg2 content esgSubNav
In This List

Bioblast seeking strategic alternatives to execute business objectives

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Bioblast seeking strategic alternatives to execute business objectives

Bio Blast Pharma Ltd. said it is exploring strategic business alternatives, including possible partnership and merger opportunities.

The clinical stage biotechnology company is considering options such as potential development and commercial partners for its investigational proprietary intravenous form of trehalose. Trehalose has been tested in humans with ocular pharyngeal muscular dystrophy and spinocerebellar ataxia type 3.

Bioblast has hired JSB-Partners to help the company execute its business development objectives.